From: Reconsidering treatment guidelines for acute myocardial infarction during the COVID-19 pandemic
 | STEMI | p-value | |
---|---|---|---|
Group 1 (n = 153) | Group 2 (n = 81) | ||
Treatment place, n (%) | |||
 Accident and emergency department | 3 (2.0) | 6 (7.4) | 0.088 |
 In-hospital | 150 (98.0) | 75 (92.6) |  |
Reperfusion therapy, n (%) | 115 (75.2) | 55 (67.9) | 0.236 |
 Primary PCI | 100 (65.4) | 20 (24.7) |  < 0.001* |
 Thrombolytic therapy | 6 (3.9) | 21 (25.9) |  < 0.001* |
 Selective PCI | 9 (5.9) | 14 (17.3) | 0.005* |
 CABG | 0 (0.0) | 0 (0.0) | - |
Conservative therapy, n (%) | 38 (24.8) | 26 (32.1) | 0.236 |
First medical contact time (min), median (IQR) | 111.0(55.0,282.0) | 223.5 (118.8,567.3) |  < 0.001* |
DTB time (min), median (IQR) | 55.0(48.0,66.0) | 67.5(50.3,116.3) | 0.021* |
Total myocardial ischemia time (min), median (IQR) | 189.0(118.0,338.0) | 383.5(198.0,654.0) | 0.018* |